Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chondroitin sulfate - Bioiberica

Drug Profile

Chondroitin sulfate - Bioiberica

Alternative Names: Chondroitin sulfate CS b-Bioactive®; Chondroitin sulphate - Bioiberica; Condro-Sorb; Condrosan; Condrosulf (Bioiberica)

Latest Information Update: 24 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bioiberica
  • Class Anti-inflammatories; Antirheumatics; Glycosaminoglycans
  • Mechanism of Action Collagen stimulants; Leucocyte elastase inhibitors; Proteoglycan stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Musculoskeletal disorders; Osteoarthritis; Rheumatic disorders

Most Recent Events

  • 24 Apr 2018 Registered for Osteoarthritis (Combination therapy) in Finland, Poland, Hungary, Austria, France (PO) through mutual recognition process from Spain
  • 24 Apr 2018 Registered for Osteoarthritis (Combination therapy) in Spain (PO)
  • 24 Apr 2018 Bioiberica plans to launch the combination drug of chondroitin sulphate and glucosamine hydrochloride by 2018.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top